腫瘍内がん治療の世界市場レポート 2025年

腫瘍内がん治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.9％で2,484億2,000万米ドルに成長します。予測期間の成長は、免疫療法の進歩、精密医療の採用拡大、臨床試験の拡大、希少がんへの注目の高まり、規制当局の支援と承認によるものと考えられます。予測期間における主な動向には、腫瘍内免疫調節薬の探索、画像誘導治療の統合、腫瘍内治療における温熱療法の応用、併用療法の臨床試験、腫瘍内治療の規制支援などがあります。

がん罹患率の上昇が、今後の腫瘍内がん治療市場の成長を牽引すると予想されます。がんは、体内の異常細胞の無秩序な増殖と拡散を特徴とする疾患群を指します。腫瘍内がん治療はがんの診断や治療に利用され、がん患者における標的外毒性、用量制限毒性、免疫刺激に伴う副作用の軽減に役立っています。例えば、2023年1月、米国を拠点とするがん擁護のための非営利団体である米国がん協会（American Cancer Society）は、2023年のがん罹患者数が195万8310人に達し、2021年の189万8160人から3.16％増加したと報告しました。このように、がんの罹患率の上昇が腫瘍内がん治療市場の成長を後押ししています。

免疫療法の統合が進むことで、腫瘍内がん治療市場の成長は今後さらに加速すると予想されます。免疫療法は、体内で産生される物質や実験室で作られる物質を利用して免疫系を強化し、体内でがん細胞の位置を特定して破壊するのを補助するがん治療の一種です。腫瘍内療法は、免疫療法が重視されつつあることに合致し、腫瘍微小環境内の免疫反応を調節する局所的で効果的なアプローチを提供します。例えば、米国保健福祉省の連邦機関である米国食品医薬品局（FDA）は2022年6月、免疫チェックポイント阻害薬（ICI）をベースとした35種類の免疫療法の併用を承認しました。その結果、免疫療法統合の増加が腫瘍内がん治療市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腫瘍内がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の腫瘍内がん治療市場：成長率分析
• 世界の腫瘍内がん治療市場の実績：規模と成長, 2019-2024
• 世界の腫瘍内がん治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界腫瘍内がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腫瘍内がん治療市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ワクチン
• チェックポイント阻害剤
• 細胞療法
• 免疫システムモジュレーター
• 養子細胞移植
• サイトカイン
• 世界の腫瘍内がん治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺がん
• 乳がん
• 悪性黒色腫
• 前立腺がん
• 頭頸部がん
• その他の用途
• 世界の腫瘍内がん治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究センター
• クリニック
• 世界の腫瘍内がん治療市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 裸のモノクローナル抗体
• 結合モノクローナル抗体
• 二重特異性モノクローナル抗体
• 世界の腫瘍内がん治療市場、ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん予防ワクチン
• 治療用がんワクチン
• 世界の腫瘍内がん治療市場チェックポイント阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1またはPD-L1阻害剤
• CTLA-4阻害剤
• 世界の腫瘍内がん治療市場細胞治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• CAR T細胞療法
• TCR療法
• 世界の腫瘍内がん治療市場免疫システム調節薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤
• Toll様受容体作動薬
• 世界の腫瘍内がん治療市場、養子細胞移植のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍浸潤リンパ球（TIL）
• 末梢血リンパ球（PBL）
• 世界の腫瘍内がん治療市場サイトカインの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターロイキン
• インターフェロン
• 腫瘍壊死因子（TNF）

第7章 地域別・国別分析

• 世界の腫瘍内がん治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腫瘍内がん治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腫瘍内がん治療市場：競合情勢
• 腫瘍内がん治療市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• F. Hoffmann-la Roche
• Takeda Pharmaceutical Company Ltd.
• GSK plc
• Ziopharm Oncology Inc.
• Celldex Therapeutics Inc.
• Astellas Pharma Inc.
• Sirnaomics
• Checkmate Pharmaceuticals Inc.
• Immunovative Therapies Ltd.
• Idera Pharmaceuticals Inc.
• Daiichi Sankyo
• Philogen S.p.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腫瘍内がん治療市場2029：新たな機会を提供する国
• 腫瘍内がん治療市場2029：新たな機会を提供するセグメント
• 腫瘍内がん治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intratumoral cancer therapies involve treatments directly administered or applied to a tumor. These therapies are specifically crafted to target tumor cells and can be employed in conjunction with other cancer treatments, such as chemotherapy and radiation therapy.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $140 billion in 2024 to $158.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $248.42 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies.

The rising incidence of cancer is anticipated to drive the growth of the intratumoral cancer therapies market in the future. Cancer refers to a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells within the body. Intratumoral cancer therapies are utilized in the diagnosis and treatment of cancer, helping to mitigate off-target toxicities, dose-limiting toxicities, and adverse effects associated with immune stimulation in patients with cancer. For example, in January 2023, the American Cancer Society, a US-based nonprofit organization dedicated to cancer advocacy, reported that the number of cancer cases reached 1,958,310 in 2023, marking a 3.16% increase from 1,898,160 in 2021. Thus, the rising incidence of cancer is fueling the growth of the intratumoral cancer therapies market.

The increasing integration of immunotherapy is expected to further accelerate the growth of the intratumoral cancer therapies market in the coming years. Immunotherapy is a type of cancer treatment that utilizes substances produced by the body or created in a laboratory to enhance the immune system and assist the body in locating and destroying cancer cells. Intratumoral therapies align with the growing emphasis on immunotherapy, offering a localized and effective approach to modulating the immune response within the tumor microenvironment. For instance, in June 2022, the United States Food and Drug Administration (FDA), a federal agency of the US Department of Health and Human Services, approved 35 immune checkpoint inhibitor (ICI)-based combination immunotherapies in 2022. Consequently, the rise in immunotherapy integration is driving the growth of the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical company focused on the research, commercialization, and discovery of prescription medications for oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition will create new opportunities for AstraZeneca in the field of cancer treatment. Neogene Therapeutics Inc. is a Netherlands-based biotechnology research firm that provides personalized therapies based on TCR genes that specifically target neoantigens found in a patient's tumor.

Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC

North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intratumoral Cancer Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intratumoral cancer therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intratumoral cancer therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intratumoral cancer therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Monoclonal Antibodies; Vaccines; Checkpoint Inhibitors; Cell Therapies; Immunes System Modulator; Adoptive Cell Transfer; Cytokines
• 2) By Application: Lung Cancer; Breast Cancer; Melanoma; Prostate Cancer; Head And Neck Cancer; Other Applications
• 3) By End Users: Hospitals; Cancer Research Centers; Clinics
• Subsegments:
• 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors
• 4) By Cell Therapies: CAR T-Cell Therapy; TCR Therapy
• 5) By Immune System Modulators: Immune Checkpoint Inhibitors; Toll-Like Receptor Agonists
• 6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs); Peripheral Blood Lymphocytes (PBLs)
• 7) By Cytokines: Interleukins; Interferons; Tumor Necrosis Factor (TNF)
• Companies Mentioned: Amgen Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intratumoral Cancer Therapies Market Characteristics

3. Intratumoral Cancer Therapies Market Trends And Strategies

4. Intratumoral Cancer Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intratumoral Cancer Therapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intratumoral Cancer Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intratumoral Cancer Therapies Market Growth Rate Analysis
• 5.4. Global Intratumoral Cancer Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intratumoral Cancer Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intratumoral Cancer Therapies Total Addressable Market (TAM)

6. Intratumoral Cancer Therapies Market Segmentation

• 6.1. Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Vaccines
• Checkpoint Inhibitors
• Cell Therapies
• Immune System Modulator
• Adoptive Cell Transfer
• Cytokines
• 6.2. Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Melanoma
• Prostate Cancer
• Head And Neck Cancer
• Other Applications
• 6.3. Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Clinics
• 6.4. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naked Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• 6.5. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.6. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Or PD-L1 Inhibitors
• CTLA-4 Inhibitors
• 6.7. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CAR T-Cell Therapy
• TCR Therapy
• 6.8. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Toll-Like Receptor Agonists
• 6.9. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Adoptive Cell Transfer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor-Infiltrating Lymphocytes (TILs)
• Peripheral Blood Lymphocytes (PBLs)
• 6.10. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interleukins
• Interferons
• Tumor Necrosis Factor (TNF)

7. Intratumoral Cancer Therapies Market Regional And Country Analysis

• 7.1. Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intratumoral Cancer Therapies Market

• 8.1. Asia-Pacific Intratumoral Cancer Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intratumoral Cancer Therapies Market

• 9.1. China Intratumoral Cancer Therapies Market Overview
• 9.2. China Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intratumoral Cancer Therapies Market

• 10.1. India Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intratumoral Cancer Therapies Market

• 11.1. Japan Intratumoral Cancer Therapies Market Overview
• 11.2. Japan Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intratumoral Cancer Therapies Market

• 12.1. Australia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intratumoral Cancer Therapies Market

• 13.1. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intratumoral Cancer Therapies Market

• 14.1. South Korea Intratumoral Cancer Therapies Market Overview
• 14.2. South Korea Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intratumoral Cancer Therapies Market

• 15.1. Western Europe Intratumoral Cancer Therapies Market Overview
• 15.2. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intratumoral Cancer Therapies Market

• 16.1. UK Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intratumoral Cancer Therapies Market

• 17.1. Germany Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intratumoral Cancer Therapies Market

• 18.1. France Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intratumoral Cancer Therapies Market

• 19.1. Italy Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intratumoral Cancer Therapies Market

• 20.1. Spain Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intratumoral Cancer Therapies Market

• 21.1. Eastern Europe Intratumoral Cancer Therapies Market Overview
• 21.2. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intratumoral Cancer Therapies Market

• 22.1. Russia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intratumoral Cancer Therapies Market

• 23.1. North America Intratumoral Cancer Therapies Market Overview
• 23.2. North America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intratumoral Cancer Therapies Market

• 24.1. USA Intratumoral Cancer Therapies Market Overview
• 24.2. USA Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intratumoral Cancer Therapies Market

• 25.1. Canada Intratumoral Cancer Therapies Market Overview
• 25.2. Canada Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intratumoral Cancer Therapies Market

• 26.1. South America Intratumoral Cancer Therapies Market Overview
• 26.2. South America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intratumoral Cancer Therapies Market

• 27.1. Brazil Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intratumoral Cancer Therapies Market

• 28.1. Middle East Intratumoral Cancer Therapies Market Overview
• 28.2. Middle East Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intratumoral Cancer Therapies Market

• 29.1. Africa Intratumoral Cancer Therapies Market Overview
• 29.2. Africa Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intratumoral Cancer Therapies Market Competitive Landscape And Company Profiles

• 30.1. Intratumoral Cancer Therapies Market Competitive Landscape
• 30.2. Intratumoral Cancer Therapies Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Intratumoral Cancer Therapies Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Johnson & Johnson
• 31.3. Eli Lilly and Company
• 31.4. F. Hoffmann-la Roche
• 31.5. Takeda Pharmaceutical Company Ltd.
• 31.6. GSK plc
• 31.7. Ziopharm Oncology Inc.
• 31.8. Celldex Therapeutics Inc.
• 31.9. Astellas Pharma Inc.
• 31.10. Sirnaomics
• 31.11. Checkmate Pharmaceuticals Inc.
• 31.12. Immunovative Therapies Ltd.
• 31.13. Idera Pharmaceuticals Inc.
• 31.14. Daiichi Sankyo
• 31.15. Philogen S.p.A.

32. Global Intratumoral Cancer Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies Market

34. Recent Developments In The Intratumoral Cancer Therapies Market

35. Intratumoral Cancer Therapies Market High Potential Countries, Segments and Strategies

• 35.1 Intratumoral Cancer Therapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intratumoral Cancer Therapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intratumoral Cancer Therapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer